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drug and is strongly associated with presence of the human
leukocyte antigen (HLA)-B*5701. Screening for HLA-B*5701
reduces the risk of developing an abacavir hypersensitivity
reaction. The carriage rate of HLA-B*5701 has not been stud-
ied in Georgia before 2009. Objective of the study was to
determine HLA-B*5701 prevalence in HIV-infected patients
in Georgia.
Methods: One hundred and sixty HIV-1 positive patients
attending Georgian Infectious Diseases, AIDS and Clinical
Immunology Research Center in 2009 within the national
treatment and care program were recruited for the study.
None of the patients had previously been treated with
abacavir. Blood samples were collected and screened for
HLA-B*5701 prior to abacavir prescription. Statistical anal-
yses were performed using SAS 9.1. Proportion with exact
95% conﬁdence interval (CI) and median with interquartile
range (IQR) are reported.
Results: Of 160 patients recruited 108 were male (67.5%)
and 42 (32.5%) - female. Median age of subjects was 32 years
(IQR 27—36). Nine patients tested HLA B*5701 positive —
5.6% (95% CI: 2.6—10.4%). Out of these nine patients 7 were
males (male prevalence: 6.5%, [95% CI: 2.6—12.9] %) and 2
females (female prevalence: 4.8% [95% CI: 0.6—16.2%]).
Conclusion: The ﬁrst prospective study of HLA-B*5701
prevalence in Georgia show similar results to the results
of other studies conducted in Caucasians. Abacavir still
remains one of the key drugs of antiretroviral regimens in
Georgia and other resource limited countries. Therefore,
prospective HLA-B*5701 screening should be implemented
in all settings where abacavir is widely used to guide selec-
tion of ART regimens and to reduce the risk of potentially
life threatening hypersensitivity reaction.
doi:10.1016/j.ijid.2010.02.2032
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Efﬁcacy of multivitamins containing phosphatidyl choline
in the mananegment of hepatotoxicity from antiretroviral
and/or antituberculous drugs
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Background: When hepatotoxicity develops in the course
of treatment with anti-tuberculosis and anti-retroviral
drugs, early improvement is important in order to con-
tinue speciﬁc treatment as early as possible. We aimed
to determine the efﬁcacy, safety and effect on quality of
life of phosphatidyl choline-containing multivitamin in the
management of antiretroviral and anti-tuberculosis hepato-
toxicity.
Methods: This was a randomized, single blinded placebo-
controlled pilot study. Included in the study were subjects
that had been enrolled to access drugs in the ARV pro-
gramme of Jos University Teaching Hospital (JUTH), who
had signed consent to participate in the parent PEPFAR
protocol and have started ARVs or antituberculous drugs.
Subjects received phosphatidyl choline-containing multivi-
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amin (Livolin forte®) or placebo (Vitamin B +Vitamin E as
n Livolin forte). Patients had either been on antitubercu-
ous or antiretroviral medications. Subjects on each arm
ere reviewed fortnightly or earlier if they had worsening
f symptoms. The liver function tests including ALT, AST
mprovements and deteriorations were noted and appro-
riate clinical decisions were taken according to standard
uidelines during the four weeks of each recruitment. The
ata were analysed and displayed in proportions and appro-
riate representations.
Results: Sixteen subjects completed the study. Five and
leven subjects were on placebo and livolin respectively.
he placebo recruitment was stopped after the ﬁfth sub-
ect due to deteriorations in liver function with associated
ncreased mortality in that group. Nine subjects were co-
nfected with Hepatitis B or C infection and one had triple
nfection of all three viruses. The baseline means ALT
or the livolin group and placebo arms were 313.19mM/L
nd 239.76mM/L respectively. There was signiﬁcant decline
f the mean ALT in the livolin group to 49.21mM/L and
8.17mM/L compared to placebo group 227.74mM/L and
29.24mM/L at two and four weeks respectively. While
oint pains reduced from 73.3% through 6.7% to 0% at the
nd of the study period in the Livolin group; the placebo
rm showed a ﬂuctuating course of 33.3%, 83.3% and 16.7%
espectively.
Conclusion: Phosphatidyl choline-containing multivita-
in demonstrated moderate beneﬁts to HIV infected
atients who develop hepatotoxicity to anti-tuberculosis or
ntiretroviral drugs when introduced early in their manage-
ent.
oi:10.1016/j.ijid.2010.02.2033
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revalence of minor populations of drug-resistant HIV-1
n newly-diagnosed treatment-naïve individuals in Singa-
ore
.-J. Sun1,∗, P. Kaur1, Y.S. Leo2
Tan Tock Seng Hospital, Singapore, Singapore
Communicable Disease Centre, Tan Tock Seng Hospital, Sin-
apore, Singapore
Background: Primary drug-resistance in HIV-1, whether in
ajor viral populations or minor populations, is a signiﬁcant
linical and public health concern. Previous studies based on
onventional direct sequencing of virus samples have shown
hat HIV-1 primary drugresistance was insigniﬁcant in Singa-
ore. But it is not clear whether this is also true to the minor
IV-1 populations of the samples because direct sequencing
sually cannot detect resistance mutations in these popula-
ions. We performed this study to determine the prevalence
f primary drug-resistance in minor HIV-1 populations.
Methods: Twenty-four PBMC-associated virus samples
rom 24 newly-diagnosed treatmentnaïve patients were ana-
yzed. PCR products of pol gene that encompass the entire
rotease gene and two-third of the reverse transcriptase
ene were ampliﬁed using an in-house method. The PCR
roducts were then column-puriﬁed for direct sequencing
nd gel-puriﬁed for clonal sequencing. The viral gene cloning
as performed using the TOPO TA cloning kit (Invitrogen).
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There’s need for collaboration between DHT and hospitals
in support supervision of lower health units. Home visits and
training of staff need to be reinforced.
doi:10.1016/j.ijid.2010.02.2036246 14
NA sequencing was performed on an Applied Biosystems
130xl Genetic Analyzer.
Results: All the sequences of the 24 samples produced
y direct sequencing were wild type, with no any known
rug-resistant mutation detected. A total of 70 viral gene
lones were obtained and sequenced for the 24 samples,
ith average 2.9 clones per sample. Clonal sequencing
etected 4 drug resistance-associated mutations (PI, V82A;
RTI, M184V, K70E; NNRTI, K101E) from the viral clones of
samples; therefore the prevalence rate of primary HIV-
drug-resistance in the minor HIV-1 populations was 16.7%
4/24).
Conclusion: Our data suggest that a considerable
roportion of treatment-naïve patients are infected by drug-
esistant HIV-1 virus in Singapore, but it was not detected by
onventional direct sequencing. This ﬁnding has important
mplications for the clinical management and public health
f HIV-1, and also suggests that more sensitive genotyping
ethod should be employed to determine the baseline of
IV-1 primary drug-resistance.
oi:10.1016/j.ijid.2010.02.2034
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revalence of HIV-1 primary resistance among HIV chron-
cally infected patients in Brazil’s Southeast region
.M.P.M. Soares1, T.R.C. Vergara1, M.M. Caseiro2, R.
ôrtes1, B. Scarpellini 1,∗, M.C.A. Sucupira1, R.S. Diaz1
Escola Paulista de Medicina - Universidade Federal de São
aulo, Sao Paulo, SP, Brazil
Centro Universitário Lusíada, Santos, SP, Brazil
Background: The prevalence of HIV primary resistance
utations has increased overtime and transmitted muta-
ions can persist in HIV-1 chronically infected patients.
tudies have shown that it is cost-effective to perform pri-
ary resistance testing when one observes a prevalence of
IV-1 primary resistance above 5% in a certain geographical
ocation. Nevertheless, such studies were conducted among
cutely/recent HIV infected patients. Our study hypothe-
is was that HIV-1 primary resistance prevalence would be
reater than 5% among HIV-1 chronically infected patients
ith indication for antiretroviral therapy in Brazil’s South-
ast (SE) region.
Methods: We have included 75 patients from 2 major
ities: 47 from Rio de Janeiro and 28 from Santos. Our pop-
lation proﬁle was non-pregnant chronically HIV-1 infected
atients with indication for antiretroviral therapy based on
ational Guidelines. HIV DNA was extracted and ampliﬁed
rom dried blood spots samples. HIV’s pol gene protease and
everse transcriptase regions were sequenced. Antiretrovi-
al resistance mutations algorithm which excludes frequent
olymorphisms was utilized.
Results: Prevalence of HIV-1 primary resistance was
7,3%. 18 mutations were observed among 13 out of 75
ncluded patients. Of these 18 mutations, 10 were related
ith NRTI’s, 8 were related to NNRTI’s and none to PI’s. The
ost commonly detected mutations were: K103N (16.6%),
69D (11.1%), M41L (11.1%). Only 4% (3 individuals) had two
lass (NRTI and NNRTI) primary resistance mutations. Theternational Congress on Infectious Diseases (ICID) Abstracts
ost prevalent HIV subtype was B (77.3%), followed by BF
33.3%), F (6.66%) and C (1.3%).
Conclusion: High primary resistance levels were observed
ccording to WHO’s deﬁnition (5—15%), suggesting being
ost-effective to perform primary resistance testing in this
egion. The increased prevalence of NNRTI’s mutations and
he absence of M184V mutations are two ﬁndings observed
n this study, contrasting with previous studies from Brazil.
oi:10.1016/j.ijid.2010.02.2035
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hallenges of antiretroviral therapy among children aged
to 15 years in Kabarole district (Western Uganda)
. Isabirye ∗, N. Kiwanuka, J. Kiguli
Makerere University School of Public Health, KAMPALA,
ganda
Background: HIV/AIDS is one of the leading causes of
ortality among children in Kabarole district. It is however
nknown how many children are on ART and there is very lit-
le documented evidence of the challenges faced by children
ged 6 to 15 years on ART.
Methods: A cross-sectional study was conducted to assess
he challenges associated with ART among children aged
to 15 years in Kabarole district. Quantitative data were
ollected using a semi structured interviewer administered
uestionnaire and qualitative using Key Informant inter-
iews. Adherence levels were assessed using self report
nformation from caretakers and children 10 years and
bove. Logistic regression models were used to estimate
dds ratios (OR’s) of adherence and their associated 95%
onﬁdence intervals.
Results: As at 30th April 2009, there were 478 children
n ARV’s in the district. Of the 332 children in the study, 51%
ere girls and 66.3% were aged 9-12 years. Using one month
ecall, 95.5% of the respondent’s adherence was 100%, 1.8%
ad 95-99% and 2.7% had adherence levels of less than 95%.
n 3-day recall, 98.5% had 100% adherence, 1.5% had less
han 95% adherence. Major challenges were a low propor-
ion of children on ART, 42.5% of respondents failed to get
ransport at least once, 51% were orphans, co-trimoxazole
tock outs at government facilities, lack of follow up and
nadequate support supervision.
Conclusion: Co-trimoxazole prophylaxis among children
ged 6 to 15 years was found to be a plausible predictor of
dherence. Challenges to ART are numerous and solutions
o them require a multi-faceted approach.
Recommendations: Co-trimoxazole prophylaxis should be
rioritised in all ART clinics for children aged 6 to 15 years.
